Neurological Features During COVID19

• Conditions: Encephalitis

• Registration Number: NCT04460599
• Lead Sponsor: Centre d'Investigation Clinique et Technologique 805

Brief Summary

Description of the neurological impairment: clinico-radiological and electrophysilogical correlations

Detailed Description

Describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral SARS COV2 infection Describe the association between neurological, respiratory and dysautonomic Determine the prognosis of neurological damages to short and long term.

Study Timeline

• Study Start: 2020-03-08
• Status Verified: 2020-07
• Study First Submitted: 2020-07-06
• Study First Submitted QC: 2020-07-06
• Study First Posted: 2020-07-07
• Last Update Submitted: 2020-07-07
• Last Update Posted: 2020-07-09
• Primary Completion: 2020-07-30
• Study Completion: 2020-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• PCR SARS COV2 positive or CT Scan
• Central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral.
• Dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, SIADH not explained by therapy or a pathology other than SARS COV 2 infection

Exclusion Criteria

• Contraindication to performing an MRI scan
• Minor
• Pregnant woman
• No follow-up possible at 6 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary	6 months	incidence of objective neurological damage

Secondary Outcome Measures

Name	Time	Method
Secondary	6 months	incidence of clinical neurological damage incidence of radiological neurological damage incidence of neurophysiological neurological damage

Trial Locations

Locations (1)

Hopital Raymond Poincare; 🇫🇷 Garches, France